Omalizumab treatment in severe adult atopic dermatitis

Asian Pacific Journal of Allergy and Immunology

Volumn 29, Issue 4, 2011, Pages 357-360

  Thaiwat, Supitchaya ^a   Sangasapaviliya, Atik ^a  

^a Phramongkutklao Hospital   (Thailand)

Author keywords

EASI score; IgE levels; Omalizumab

Indexed keywords

CETIRIZINE; CORTICOSTEROID; CYCLOSPORIN; DESLORATADINE; EMOLLIENT AGENT; FEXOFENADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; HYDROXYZINE; IMMUNOGLOBULIN E; LORATADINE; OMALIZUMAB; PREDNISOLONE; STEROID; TACROLIMUS; TRIAMCINOLONE;

ABSENCE OF SIDE EFFECTS; ADULT; ALLERGIC RHINITIS; ARTICLE; ATOPIC DERMATITIS; BLOOD CELL COUNT; BLOOD SAMPLING; CASE REPORT; CHRONIC DISEASE; CLINICAL ASSESSMENT TOOL; CLINICAL EXAMINATION; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ECZEMA; ECZEMA AREA AND SEVERITY INDEX; FECES ANALYSIS; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LABORATORY TEST; MALE; MULTIPLE CYCLE TREATMENT; PRURITUS; SCORING SYSTEM; SYMPTOM; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTI-ALLERGIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; DERMATITIS, ATOPIC; HUMANS; IMMUNOGLOBULIN E; MALE; YOUNG ADULT;

EID: 84855240653     PISSN: 0125877X     EISSN: 22288694     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Act Derm Venerol Suppl (Stockh). 1980;92:44-7.
2. Stingl G. IgE-mediated, FcεRI-dependent allergen presentation: a pathogenetic factor in atopic dermatitis. J Am Acad Dermatol. 2001;45:S17-20.
3. Hanifin JM, Chan S. Biochemical and immunologic mechanisms in atopic dermatitis: new targets for emerging therapies. J Am Acad Dermatol. 1999;41:72-7.
4. Tofte SJ, Hanifin JM. Current management and therapy of atopic dermatitis. J Am Acad Dermatol. 2001; 44:S13-6.
5. Busse W, Corren J, Lanier BQ, McAlary M, Folwer-Taylor A, Cioppa GD, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108:184-9.
6. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001;10:11-8.
7. Graves JE, Nunley K, Heffernan MP. Off-label uses of biologics in dermatology: Rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept. J Am Acad Dermatol. 2007;56:e55-79.
8. Lane JE, Cheyney JM, Lane TN, Kent DE, Cohen DJ. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 2006;54:68-72.
9. Sheinkopf LE, Rafi AW, Do LT, Katz RM, Klaustermeyer WB. Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy asthma proc 2008;29:530-7.
10. Leynadier F, Doudou O, Gaouar H, Le Gros V, Bourdeix I, Guyomarch-Cocco L, et al. Effect of omalizumab in health care workers with occupational latex allergy. J Allergy Clin Immunol. 2004;113: 360-1.
11. Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy. 2004; 59: 709-17.
12. Hagel I, Di Prisco MC, Goldblatt J, Le Souef PN. The role of parasites in genetic susceptibility to allergy: IgE, helminthic infection and allergy, and the evolution of the human immune system. Clin Rev Allergy Immunol. 2004;26:75-83.
13. Lin H, Boesel KM, Griffith DT, Prussin C, Foster B, Romero FA, et al. Omalizumab rapidly decreases nasal allergic response and FCεRI on basophils. J Allergy Clin Immunol. 2004;113:297-302.
14. Corren J, Diaz-Sanchez D, Saxon A, Deniz Y, Reimann J, Sinclair D, et al. Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesis. Ann Allergy Asthma Immunol. 2004; 93: 243-8.
15. Amrol D. Anti-immunoglobulin E in the treatment of refractory atopic dermatitis. South Med J. 2010;103:554-8.
16. Park SY, Choi MR, Na JI, Youn SW, Park KC, Huh CH. Recalcitrant atopic dermatitis treated with omalizumab. Ann Dermatol. 2010;22:349-52.
17. Krathen RA, Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol. 2006;53:338-40.